Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem‐cell transplantation: Real‐life experience

Buccheri, Valéria; Fatobene, Giancarlo; Santos, Fernanda Maria; Velasques, Rodrigo Dolphini; Bellesso, Marcelo; Atanazio, Marcelo Junqueira; Rocha, Vanderson

doi:10.1002/hon.2796

Cited by 1 publication

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The published literature on the management of refractory or relapsed adult patients in Brazil is relatively scarce, with the exception of retrospective series on ASCT [102][103][104][105][106]. Based on 694 patients undergoing frontline therapy, investigators from the University of Sao Paulo reported on 188 CHL patients with refractory or relapsed CHL, 107 of whom receiving ASCT from 1995 to 2014 [102].…”

Section: Published Experience With Transplantationmentioning

confidence: 99%

“…The authors concluded that ASCT is efficacious and safe of in the treatment of refractory and relapsed CHL at a large public cancer center in Brazil, and that novel agents, including BV and CPIs are likely to improve transplantation outcomes in in the near future. A second case series from the same university hospital provides insights on the use of nivolumab after ASCT [ 103 ]. Of 171 patients with CHL treated between 2015 and 2019, 25 (16%) had primary refractoriness, and an additional 15 patients relapsed after a CR.…”

Section: Current Prospects and Experience In Brazilmentioning

confidence: 99%

See 1 more Smart Citation

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

Xavier,

Farias,

Neto

et al. 2023

Oncotarget

View full text Add to dashboard Cite

Classic Hodgkin lymphoma (CHL), which accounts for 90-95% of all cases of Hodgkin lymphoma, is the most frequent cancer in adolescents and the most frequent lymphoma in adolescents and young adults. Despite progressive improvements over past decades and the general sensitivity of CHL to frontline chemotherapy, approximately 10-15% of patients have refractory disease that either does not respond to such therapy or progresses after an initial partial response. In patients with refractory or relapsed disease, standard treatment until recently consisted mainly of salvage chemotherapy, in many cases followed by high-dose chemotherapy and autologous stem-cell transplantation. However, improved understanding of the pathobiology of CHL, coupled with the introduction of novel agents, has markedly changed the treatment landscape in the past decade. Although refractory or relapsed CHL continues to be challenging, the therapeutic landscape is undergoing profound changes brought about by novel agents, particularly brentuximab vedotin and immunotherapy. In this review, we discuss the most salient treatment options for adult patients with refractory or relapsed CHL, with a special focus on the Brazilian healthcare setting, which is constrained by inherent characteristics of this system. In the attempt to balance efficacy, safety and tolerability, practicing physicians must rely on clinical trials and on results from real-world studies, and use their own point of view and experience, as well as patient characteristics and previous therapy, to make treatment decisions for refractory or relapsed CHL. Oncotarget 978 www.oncotarget.com * According to the German Hodgkin Study Group risk group classification [41].

show abstract